Amgen, Inc. (NASDAQ:AMGN) Shares Sold by Delta Financial Advisors LLC
Delta Financial Advisors LLC trimmed its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 1.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 11,383 shares of the medical research company’s stock after selling 152 shares during the period. Delta Financial Advisors LLC’s holdings in Amgen were worth $2,744,000 at the end of the most recent reporting period.
Several other hedge funds also recently bought and sold shares of the company. BlackRock Inc. grew its stake in Amgen by 3.4% in the 2nd quarter. BlackRock Inc. now owns 47,717,316 shares of the medical research company’s stock worth $8,793,346,000 after acquiring an additional 1,585,911 shares during the period. State Street Corp grew its stake in Amgen by 0.9% in the 4th quarter. State Street Corp now owns 26,226,343 shares of the medical research company’s stock worth $6,322,385,000 after acquiring an additional 236,791 shares during the period. Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in shares of Amgen by 0.4% in the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,385,368 shares of the medical research company’s stock valued at $575,041,000 after purchasing an additional 10,043 shares during the last quarter. Parametric Portfolio Associates LLC boosted its holdings in shares of Amgen by 7.0% in the 3rd quarter. Parametric Portfolio Associates LLC now owns 2,353,360 shares of the medical research company’s stock valued at $455,399,000 after purchasing an additional 154,094 shares during the last quarter. Finally, California Public Employees Retirement System boosted its holdings in shares of Amgen by 21.2% in the 3rd quarter. California Public Employees Retirement System now owns 1,567,552 shares of the medical research company’s stock valued at $303,337,000 after purchasing an additional 274,146 shares during the last quarter. Institutional investors own 76.69% of the company’s stock.
In other Amgen news, CFO David W. Meline sold 8,737 shares of the business’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $234.36, for a total value of $2,047,603.32. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director R Sanders Williams sold 425 shares of the business’s stock in a transaction on Thursday, February 6th. The stock was sold at an average price of $233.72, for a total transaction of $99,331.00. Following the completion of the transaction, the director now owns 4,988 shares in the company, valued at approximately $1,165,795.36. The disclosure for this sale can be found here. Insiders sold a total of 27,426 shares of company stock worth $6,351,866 in the last quarter. 0.25% of the stock is currently owned by company insiders.
Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, January 30th. The medical research company reported $3.64 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.47 by $0.17. Amgen had a net margin of 33.57% and a return on equity of 85.52%. The business had revenue of $6.20 billion for the quarter, compared to analyst estimates of $6.04 billion. During the same quarter in the previous year, the business posted $3.42 EPS. The business’s quarterly revenue was down .5% on a year-over-year basis. On average, analysts predict that Amgen, Inc. will post 15.56 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 14th will be issued a $1.60 dividend. The ex-dividend date is Thursday, February 13th. This represents a $6.40 dividend on an annualized basis and a yield of 2.88%. This is a positive change from Amgen’s previous quarterly dividend of $1.45. Amgen’s payout ratio is currently 39.14%.
AMGN has been the topic of a number of research analyst reports. Raymond James initiated coverage on shares of Amgen in a report on Monday, December 23rd. They issued a “market perform” rating on the stock. Credit Suisse Group reiterated a “buy” rating and issued a $252.00 price target on shares of Amgen in a report on Sunday, February 2nd. Mizuho reiterated a “hold” rating and issued a $215.00 price target on shares of Amgen in a report on Thursday, January 30th. Cowen reiterated a “buy” rating on shares of Amgen in a report on Friday, January 31st. Finally, Citigroup lifted their price target on shares of Amgen from $245.00 to $275.00 and gave the company an “in-line” rating in a report on Thursday, January 23rd. Three research analysts have rated the stock with a sell rating, twelve have issued a hold rating and twelve have given a buy rating to the company. Amgen currently has a consensus rating of “Hold” and a consensus price target of $237.33.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
See Also: Do You Need a Fiduciary?
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.